EQT to buy in silico drug development service provider Certara from Arsenal

Fierce Biotech reports that private equity firm EQT is acquiring in silico drug development service provider Certara from Arsenal Capital Partners, a deal that values the Contract Research Organisation (CRO) at $850 million, announced by Arsenal on Tuesday 11 July 2017.

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies.

Certara previously bought SymCyp, a Sheffield based company, started by Amin Rostami, a professor at The University of Sheffield and now at the University of Manchester.

Read more…